Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation

Experimental Cell Research

Volumn 252, Issue 1, 1999, Pages 134-143

  Pucci, Bruna ^a   Bellincampi, Lorenza ^a   Tafani, Marco ^a   Masciullo, Valeria ^a   Melino, Gerry ^b   Giordano, Antonio ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; CD95 Bcl 2; Osteosarcoma; Paclitaxel

Indexed keywords

CASPASE 3; CASPASE INHIBITOR; FAS ANTIGEN; PACLITAXEL; PROTEIN BCL 2; PROTEINASE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

EID: 0033544005     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4591     Document Type: Article

References (48)

1. Meyers P. A., Gorlick R. Osteosarcoma. Pediatr. Clin. 44:1997;973-989.
2. Bruland O. S., Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer. 33:1997;1725-1731.
3. Davis A. M., Bell R. S., Goodwin P. J. Prognostic factors in osteosarcoma: A critical review. J. Clin. Oncol. 12:1994;423-431.
4. Morimoto Y., Ohba T., Kobayashi S., Haneji T. The protein phosphatase inhibitors okadaic acid and calyculin A induce apoptosis in human osteoblastic cells. Exp. Cell Res. 230:1997;181-186.
5. Wani M. C., Taylor H. L., Wall M. E., Coggan P., Mcphail A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:1971;2325-2327.
6. Douros J., Suffness M. New natural product of interest under development at the National Cancer Institute. Cancer Chemother. Pharmacol. 1:1978;91-100.
7. National Cancer Institute1993. Clinical Brochure: Taxol (NSC 125973), pp. 6-12, National Division of Cancer Treatment, Bethesda, MD.
8. Riondel J., Jacrot M., Picot F., Beriel H., Mouriquand C., Potier P. Therapeutic response to taxol of six tumors xenografted into nude mice. Cancer Chemother. Pharmacol. 17:1986;137-142.
9. Riondel J., Jacrot M., Nissou M. F., Picot F., Beriel H., Mouriquand C., Potier P. Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice. Anticancer Res. 8:1988;387-390.
10. Rowinsky E., Donehower R. Paclitaxel (taxol). N. Engl. J. Med. 332:1995;1004-1014.
11. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem. 256:1981;10435-10441.
12. Schiff P. B., Horwitz S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA. 77:1980;1561-1565.
13. Roberts J. R., Alison D. C., Donehower R. C., Rowinsky E. K. Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res. 50:1990;710-716.
14. Horwitz S. B. Mechanism of action of taxol. Trends Pharmacol. Sci. 13:1992;134-136.
15. Donaldson K. L., Goolsby G. L., Wahl A. F. Cytotoxicity of the anticancer agents cis-platin and taxol during cell proliferation and cell cycle. Int. J. Cancer. 57:1994;847-855.
16. Bhalla K., Ibrado A. M., Tourkina E., Tang C., Mahoney M. E., Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 7:1993;563-568.
17. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M. A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry. 13:1992;795-808.
18. Piacentini M., Annicchiarico-Petruzzelli M., Oliviero S., Piredda L., Biedler J. L., Melino G. Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: Correlation with cell death by apoptosis. Int. J. Cancer. 52:1992;271-278.
19. Melino G., Annicchiarico-Petruzzelli M., Piredda L., Candi E., Gentile V., Davies P. A. J., Piacentini M. Tissue transglutaminase and apoptosis: Sense and antisense transfection studies with human neuroblastoma cells. Mol. Cell Biol. 14:1994;6584-6596.
20. Gianni L., Kearns C. M., Giani A., Capri G., Vigano L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic-pharmacodynamic relationships in humans. J. Clin. Oncol. 13:1995;180-190.
21. Yang E., Korsmeyer S. J. Molecular thanatopsis: A discourse on the BCL-2 family and cell death. Blood. 88:1996;386-401.
22. Farrow S. N., Brown R. New members of the Bcl-2 family and their protein partners. Curr. Opin. Gen. Dev. 6:1996;45-49.
23. Haldar S., Basu A., Croce C. M. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
24. Zhivotovsky B., Burgess D. H., Schlegel J., Porn M. I., Vanags D., Orrenius S. Proteases in Fas-mediated apoptosis. J. Biol. Chem. 64:1997;43-49.
25. Debatin K. M., Beltinger C., Bohler T., Fellenberg J., Friesen C., Fulda S., Herr I., Loss M., Scheuerpflug C., Sieverts H., Stahnke K. Regulation of apoptosis through CD95(APO-1/Fas) receptor ligand interaction. Biochem. Soc. Trans. 25:1997;405-410.
26. Friesen C., Fulda S., Debatin K. M. Deficient activation of the CD95(APO-1/Fas) system in drug resistant cells. Leukemia. 11:1997;1833-1841.
27. Herr I., Wilhelm D., Bohler T., Angel P., Debatin K. M. Activation of CD95(APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16:1997;6200-6208.
28. Gamen S., Anel A., Lasierra P., Alava M. A., Martinez-Lorenzo M. J., Pineiro A., Naval J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett. 417:1997;360-364.
29. Lisignoli G., Toneguzzi S., Cattini L., Pozzi C., Facchini A. Different expression pattern of cytokine receptors by human osteosarcoma cell line. Int. J. Oncol. 12:1998;899-903.
30. Fellenberg J., Mau H., Scheuerpflug C., Ewerbeck V., Debatin K. M. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells cytokines. Int. J. Cancer. 72:1997;536-542.
31. Saunders D. E., Lawrence W. D., Christensen C., Wappler N. L., Ruan H., Deppe G. Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int. J. Cancer. 70:1997;214-220.
32. Milas L., Hunter N. R., Kurdoglu B., Mason K. A., Meyn R. E., Stephens L. C., Peters L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 35:1995;297-303.
33. Furlong I. J., Mediavilla C. L., Ascaso R., Rivas A. L., Collins M. K. L. Induction of apoptosis by valinomycin: Mitochondrial permeability transition causes intracellular acidification. Cell Death Differ. 5:1998;214-221.
34. Fang G., Chang B. S., Kim C. N., Perkins C., Thompson C. B., Bhalla K. N. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 58:1998;3202-3208.
35. Ibrado A. M., Liu L., Bhalla K. Bcl-XL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res. 57:1997;1109-1115.
36. Frankel A., Buckman R., Kerbel R. S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumors spheroids. Cancer Res. 57:1997;2388-2393.
37. Poruchynsky M. S., Wang E. E., Rudin C. M., Blagosklonny M. V., Fojo T. Bcl-XL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 58:1998;3331-3338.
38. Roth W., Wagenknecht B., Grimmel C., Dichgans J., Weller M. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br. J. Cancer. 77:1998;404-411.
39. Blagosklonny M. V., Giannakakou P., El-Deiry W. S., Kingston D. G. I., Higgs P. I., Neckers L., Fojo T. Raf-1/Bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res. 57:1997;130-135.
40. Das K. C., White C. W. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272:1997;14914-14920.
41. Ding A., Chen B., Fuortes M., Blum E. Association of mitogen-activated protein kinases with microtubules in mouse macrophages. J. Exp. Med. 183:1996;1899-1904.
42. Nishio K., Arioka H., Ishida T., Fukumoto H., Kurokawa H., Sata M., Ohata M., Saijo N. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int. J. Cancer. 63:1995;688-693.
43. Shen S. C., Huang T. S., Jee S. H., Kuo M. L. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphobol-13-acetate in human breast MCF-carcinoma cells. Cell Growth Differ. 9:1998;23-29.
44. Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell T. J., Hung M. C. Overexpression of Erb2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34cdc2 kinase. Mol. Cell. 2:1998;581-591.
45. Jun C. D., Choi B. M., Kim H. M., Chung H. T. Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J. Immunol. 154:1995;6541-6547.
46. Henricson B. E., Carboni J. M., Burkhardt A. L., Vogel S. N. LPS and taxol activated Lyn kinase autophosphorylation in Lps(n), but not in Lps(d), macrophages. Mol. Med. 1:1995;428-435.
47. Wolfson M., Yang C. P., Horwitz S. B. Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. Int. J. Cancer. 70:1997;248-252.
48. Amato S. F., Swart J. M., Berg M., Wanebo H. J., Metha S. R., Chiles T. C. Transient stimulation of the c-jun-NH2-terminal kinase/activator protein1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 58:1998;241-247.